What is the level of liabilities of Gilead Sciences this year?
Gilead Sciences has a debt balance of 39.29 B USD this year.
In 2024, Gilead Sciences's total liabilities amounted to 39.29 B USD, a -6.29% difference from the 41.93 B USD total liabilities in the previous year.
In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.
Gilead Sciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Gilead Sciences's financial stability, operational efficiency, and long-term viability.
By comparing Gilead Sciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Gilead Sciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Gilead Sciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Gilead Sciences has a debt balance of 39.29 B USD this year.
The liabilities of Gilead Sciences have increased by -6.29% dropped compared to the previous year.
High liabilities can pose a risk for investors of Gilead Sciences, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Gilead Sciences has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Gilead Sciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Gilead Sciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Gilead Sciences include investments, acquisitions, operating costs, and sales development.
The liabilities of Gilead Sciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Gilead Sciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 3.38 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.
The current dividend yield of Gilead Sciences is 3.38 %.
Gilead Sciences pays a quarterly dividend. This is distributed in the months of January, April, July, October.
Gilead Sciences paid dividends every year for the past 15 years.
For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.71 %.
Gilead Sciences is assigned to the 'Health' sector.
To receive the latest dividend of Gilead Sciences from 9/27/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
The last dividend was paid out on 9/27/2024.
In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.
The dividends of Gilead Sciences are distributed in USD.
The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.